Personalized Drug Therapy Is Here! An Update on Genetic Tools and Clinical Decision Support Available to Guide Drug and Dose Selection Today
A person’s response to a drug is dependent on many factors, including genetic variation. Targeted genetic testing can predict adverse drug reactions and therapeutic failure, as well as the need for non-standard dosing of several clinically important drugs. Expert consensus regarding implementing specific drug-gene associations has led to clinical decision support that can guide drug and dose selection based on genetic test results. This video lecture will offer examples of how genetic testing can be used to personalize pharmacotherapy decisions.
Originally presented on September 13, 2016 in Salt Lake City, Utah.
Gwen McMillin, PhD, DABCC(CC,TC)
Medical Director, Toxicology and Pharmacogenetics, ARUP Laboratories
Professor (clinical) of Pathology, University of Utah School of Medicine
Dr. McMillin is a professor of pathology at the University of Utah School of Medicine. She received her PhD in pharmacology and toxicology from the University of Utah and is certified by the American Board of Clinical Chemistry in clinical chemistry and toxicological chemistry. Dr. McMillin is actively involved in professional associations such as the International Association of Therapeutic Drug Monitoring and Clinical Chemistry (IATDMCT), the American Association for Clinical Chemistry (AACC), and the College of American Pathologists (CAP). Her primary interests include detection of neonatal drug exposures, as well as clinical applications and implementation of pharmacogenomics.
After this presentation, participants will be able to:
- Describe how genetic testing can predict a drug response phenotype.
- List examples of drug-gene pairs with clinical decision support.
- Discuss limitations of pharmacogenetics testing and implementation of gene-based drug and dose selection.
University of Utah School of Medicine, Department of Pathology, and ARUP Laboratories